Pathology & Oncology Research

, Volume 15, Issue 3, pp 369–374 | Cite as

CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer

  • Zhao-dong Han
  • Xue-cheng Bi
  • Wei-jun Qin
  • Hui-chan He
  • Qi-shan Dai
  • Jun Zou
  • Yong-kang Ye
  • Yu-xiang Liang
  • Guo-hua Zeng
  • Zhi-nan Chen
  • Wei-de ZhongEmail author
Original Paper


Extracellular matrix metalloproteinase inducer (EMMPRIN, also named as CD147) is a multifunctional membrane glycoprotein over-expressed in many kinds of human solid tumors. It has been demonstrated to be involved in tumor invasion and angiogenesis. The aim of this study was to analyze the clinicopathological characteristics of the expression of CD147 in human prostate cancer (PCa), and to evaluate its clinical significance in the histologic classification and prognosis of PCa. CD147 protein expression in paraffin-embedded specimens gathered from 62 cases of PCa and 30 cases of benign prostatic hyperplasia (BPH) were detected by the method of immunohistochemistry. The association of CD147 protein expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. CD147 expression were positively expressed in 51/62 (82.3%) of PCa and 4/30 (13.3%) of BPH cases, respectively. The positive expression rate of CD147 in PCa tissues was significantly higher than that in BPH. The positive expression of CD147 was dramatically associated with TNM grade (p < 0.001), the depth of the prostatic wall invasion (p = 0.008), GLEASON Score (p = 0.001) and Histologic grade (p = 0.001). The patients with CD147 expression were associated with a poor prognosis of PCa (p = 0.01) and the survival rate of the patients with a strong positive expression of CD147 was the lowest (p = 0.01). The results suggest that the expression of CD147 may be an important feature of PCa and the detection of its expression may benefit us in the prediction of the prognosis of PCa.


Prostate cancer CD147 Clinical pathology Diagnosis Prognosis 



This work was supported by grants from the Natural Science Foundation of Guangdong Province (No.04003650) and the Key Programs of Science and Technology of Guangzhou city (No. 200323 – E4053) and National High Technology Research and Development Project of China (No.2006AA02A245).


  1. 1.
    Schrgder FH, Wildhagen MF, ERSPC (2001) Screening for prostate cancer: evidence and perspectives. BJU Int 88:811–817CrossRefGoogle Scholar
  2. 2.
    Holmberg L, Bill-Axelson A, Helgesen F (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New Eng J Med 347:781–789CrossRefPubMedGoogle Scholar
  3. 3.
    Hochreiter WW (2008) The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 40:130–133CrossRefPubMedGoogle Scholar
  4. 4.
    Loeb S, Catalona WJ (2008) What to do with an abnormal PSA test. Oncologist 13:299–305CrossRefPubMedGoogle Scholar
  5. 5.
    Kehinde EO, Maghrebi MA, Anim JT (2008) The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol 15:3967–3974PubMedGoogle Scholar
  6. 6.
    Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai Z et al (2006) Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via rna interference. Cancer Biology & Therapy 5:608–614Google Scholar
  7. 7.
    Gabison EE, Mourah S, Steinfels E et al (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas. Am. J. Pathol 166:209–219PubMedGoogle Scholar
  8. 8.
    Li Y, Shang P, Qian A et al (2003) Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroente 9:2174–2177Google Scholar
  9. 9.
    Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C (2004) The microvesicle as a vehicle for EMMPRIN in tumorstromal interactions. Oncogene 23:956–963CrossRefPubMedGoogle Scholar
  10. 10.
    Millimaggi D, Mari M, D’Ascenzo S, Carosa E, Jannini EA, Zucker S et al (2007) Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9:349–357CrossRefPubMedGoogle Scholar
  11. 11.
    Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 56:359–367CrossRefPubMedGoogle Scholar
  12. 12.
    London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10:823–832CrossRefPubMedGoogle Scholar
  13. 13.
    Mi Z, Oliver T, Guo H, Gao C, Kuo PC (2007) Thrombin-cleaved COOH (-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 67:4088–4097CrossRefPubMedGoogle Scholar
  14. 14.
    Kakehi Y (2003) Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin oncol. 33:1–5CrossRefPubMedGoogle Scholar
  15. 15.
    Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM et al (2007) Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 98:1767–1774CrossRefPubMedGoogle Scholar
  16. 16.
    Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G et al (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119:1800–1810CrossRefPubMedGoogle Scholar
  17. 17.
    Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H et al (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434–439PubMedGoogle Scholar
  18. 18.
    Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S et al (2002) EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19:697–702CrossRefPubMedGoogle Scholar
  19. 19.
    Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMedGoogle Scholar
  20. 20.
    Biswas C (1982) Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 109:1026–1034CrossRefPubMedGoogle Scholar
  21. 21.
    Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ et al (2005) MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 22:565–573CrossRefPubMedGoogle Scholar
  22. 22.
    Sun J, Hemler ME (2001) Regulation of MMP-1 and MMP-2production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer research 61:2276–2281PubMedGoogle Scholar
  23. 23.
    Marieb EA, Zoltan-Jones A, Li R (2004) Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Research. 64:1229–1232CrossRefPubMedGoogle Scholar
  24. 24.
    Li HG, Xie DR, Shen XM (2005) Clinicopathological significance of expression of paxillin, syndecan-l and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 11:1445–1451PubMedGoogle Scholar
  25. 25.
    Lanyi M, Antonescu CR (2002) The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 160:1215–1221Google Scholar
  26. 26.
    Seitz C, Djavan B (2006) Biological markers of prostate cancer. Ann Urol (Paris). 40:329–335Google Scholar
  27. 27.
    Zucker S, Hymowitz M, Rollo EE et al (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158:1921–1928PubMedGoogle Scholar
  28. 28.
    Tang Y, Kesavan P, Marian T (2004) Tumor-stroma interaction:positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expressio and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2:73–80PubMedGoogle Scholar
  29. 29.
    Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99:520–528CrossRefPubMedGoogle Scholar
  30. 30.
    Jia L, Wang H, Qu S, Miao X, Zhang J (2008) CD147 regulates vascular endothelial growth factor-expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB Life 60:57–63PubMedCrossRefGoogle Scholar
  31. 31.
    Tang Y, Nakada MT, Rafferty P, McCabe FL, Millar H, Cunningham M et al (2006) Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 4:371–377CrossRefPubMedGoogle Scholar
  32. 32.
    Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y (2008) The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57(9):1367–1379 doi: 10.1007/s00262-008-0473-x CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2008

Authors and Affiliations

  • Zhao-dong Han
    • 1
  • Xue-cheng Bi
    • 2
  • Wei-jun Qin
    • 3
  • Hui-chan He
    • 1
  • Qi-shan Dai
    • 1
  • Jun Zou
    • 1
  • Yong-kang Ye
    • 1
  • Yu-xiang Liang
    • 1
  • Guo-hua Zeng
    • 4
  • Zhi-nan Chen
    • 3
  • Wei-de Zhong
    • 1
    • 5
    Email author
  1. 1.Guangzhou First Municipal People’s HospitalAffiliated Guangzhou Medical CollegeGuangzhouChina
  2. 2.Southern Medical UniversityGuangzhouChina
  3. 3.Department of Cell Biology & Cell Engineering Research CentreFourth Military Medical UniversityXi’anChina
  4. 4.First Affiliated Hospital of Guangzhou Medical CollegeGuangzhouChina
  5. 5.Department of Urology, Guangzhou First Municipal People’s Hospital, Southern Medical UniversityAffiliated Guangzhou Medical CollegeGuangzhouChina

Personalised recommendations